BRPI0506704A - composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético - Google Patents

composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético

Info

Publication number
BRPI0506704A
BRPI0506704A BRPI0506704-9A BRPI0506704A BRPI0506704A BR PI0506704 A BRPI0506704 A BR PI0506704A BR PI0506704 A BRPI0506704 A BR PI0506704A BR PI0506704 A BRPI0506704 A BR PI0506704A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
proton pump
pump inhibitor
pharmaceutically acceptable
release form
Prior art date
Application number
BRPI0506704-9A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of BRPI0506704A publication Critical patent/BRPI0506704A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES FARMAçêUTICAS COMPREENDENDO INIBIDOR DA BOMBA DE PRóTONS E AGENTE PRóCINéTICO. Composições farmacêuticas orais e processo para o prepare das mesmas são proporcionados compreendendo pelo menos um agente se supressão de ácido gástrico, de preferência um inibidor da bomba de prótons ou seus sais, ésteres, hidratos, derivados ou pró-fármacos farmaceuticamente aceitáveis, e um ou mais agentes pró-cinéticos ou seus sais, ésteres, hidratos, derivados ou pró-fármacos farmaceuticamente aceitáveis, opcionalmente com outros excipientes farmaceuticamente aceitáveis, caracterizada pelo fato de que o agente de supressão de ácido gástrico está presente em uma forma com liberação retardada para proporcionar uma dose de carga inicial e uma forma com liberação retardada para proporcionar uma dose com um tempo de retardo; contando que o agente pró-cinético não seja formulado usando um polímero para controle de taxa hidrofílica e não esteja presente em uma forma com liberação sustentada. Método de tratamento de doença de refluxo esofageal, esofagite de refluxo, úlcera péptica, úlcera gástrica e outros distúrbios relacionados ao ácido gástrico através de administração, a um paciente que precisa do mesmo, de tal composição farmacêutica também é proporcionado.
BRPI0506704-9A 2004-01-06 2005-01-05 composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético BRPI0506704A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN21DE2004 2004-01-06
IN25DE2004 2004-01-06
PCT/IN2005/000002 WO2005065664A1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Publications (1)

Publication Number Publication Date
BRPI0506704A true BRPI0506704A (pt) 2007-05-02

Family

ID=34751863

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506704-9A BRPI0506704A (pt) 2004-01-06 2005-01-05 composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético

Country Status (11)

Country Link
US (1) US20070160664A1 (pt)
EP (1) EP1729743A1 (pt)
AP (1) AP2006003703A0 (pt)
AU (1) AU2005204014B2 (pt)
BR (1) BRPI0506704A (pt)
CA (1) CA2552627A1 (pt)
EA (1) EA012261B1 (pt)
NZ (1) NZ548780A (pt)
RS (1) RS20050796A (pt)
WO (1) WO2005065664A1 (pt)
ZA (1) ZA200606409B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2008012621A2 (en) * 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
WO2011136750A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Pharmaceutical compositions inducing synergistic effect
JPWO2012018056A1 (ja) * 2010-08-03 2013-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 圧縮組成物
BRPI1103093A2 (pt) * 2011-06-03 2013-07-02 Eurofarma Laboratarios Ltda composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral
KR20130024644A (ko) * 2011-08-31 2013-03-08 한국유나이티드제약 주식회사 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법
JP2018518521A (ja) 2015-06-26 2018-07-12 コリア ユナイテッド ファーマ． インコーポレーテッド モサプリドとラベプラゾールの複合製剤
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Also Published As

Publication number Publication date
AU2005204014A1 (en) 2005-07-21
US20070160664A1 (en) 2007-07-12
RS20050796A (en) 2007-08-03
WO2005065664A8 (en) 2005-10-20
ZA200606409B (en) 2008-06-25
AP2006003703A0 (en) 2006-08-31
CA2552627A1 (en) 2005-07-21
AU2005204014B2 (en) 2008-02-28
EP1729743A1 (en) 2006-12-13
WO2005065664A1 (en) 2005-07-21
NZ548780A (en) 2008-09-26
EA200601286A1 (ru) 2007-02-27
EA012261B1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
RU2013121788A (ru) Ингибиторы репликации вич
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
BRPI0912842A8 (pt) composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
BRPI0506704A (pt) composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético
BR112012026255A2 (pt) composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
BR0311419A (pt) Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento
BRPI0516454A (pt) compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR112014010228A2 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
AR086652A1 (es) Metodos de tratamiento, composiciones farmaceuticas y usos de los mismos
JP2015038135A5 (pt)
JP2013529665A5 (pt)
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
BR112015030664A2 (pt) combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.